Optical genome mapping: a promising new tool t... - CLL Support

CLL Support

23,253 members39,949 posts

Optical genome mapping: a promising new tool to assess genomic complexity in CLL

bennevisplace profile image
2 Replies

In CLL, cytogenetic testing relies on a few well-established techniques powerfulpatients.org/2019/1... while the new method of optical genome mapping (OGM) remains strictly experimental.

Preliminary research, though, does suggest that OGM can enhance cytogenomic assessment in CLL. Conclusions from ncbi.nlm.nih.gov/pmc/articl...

In summary, we have confirmed that OGM is a valuable tool for the cytogenomic assessment of CLL patients. It not only effectively detects most of the abnormalities defined by the combination of standard methods in a single test but also provides a more comprehensive genomic analysis allowing an enhanced interpretation. Despite a few abnormalities still being missed due to OGM limitations, these are expected to be addressed by the technical and analytical improvements of upcoming Bionano Access upgrades. As for its utility for risk stratification, herein, for the first time, we have demonstrated the association of an increasing number of abnormalities by OGM with a worse clinical evolution of CLL patients. Nonetheless, further studies in larger unselected cohorts are required to define standard genomic complexity criteria by OGM and to define the clinical significance of the novel abnormalities underscored by this technology. In conclusion, OGM is a new methodology that could potentially replace current cytogenomic methodologies for the routine management of CLL patients in the future.

If anyone is interested to know more about the technology, you can register for a webinar presented by Dr. Adam Smith, who will describe how his organization [Cancer Cytogenetics Laboratory University Health Network, Toronto] has evaluated optical genome mapping as a first-line test for hematologic malignancies specifically focusing on acute myeloid leukemia and replacing a legacy eosinophilic leukemia FISH panel insideprecisionmedicine.com...

Written by
bennevisplace profile image
bennevisplace
To view profiles and participate in discussions please or .
Read more about...
2 Replies
Jm954 profile image
Jm954Administrator

I think it sounds very promising for the future. :)

bennevisplace profile image
bennevisplace in reply toJm954

Yes I thought so. I think the webinar will be worth watching even though focusing on AML.

Not what you're looking for?

You may also like...

Potential Early Drivers of Disease in Treatment-Naive CLL Identified

This study reinforces others regarding mutations that predict a short time to first treatment....
Jm954 profile image
Administrator

A Tool to Select Candidates for Allogeneic Hematopoietic Cell Transplant in CLL but do we need it?

August 14, 2019 From this it's clear that transplant is not an easy decision to make and the new...
Jm954 profile image
Administrator

VenR in Relapsed CLL: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from MURANO 3 study

This is an important evaluation and insight into how your CLL profile affects your response to VR...
Jm954 profile image
Administrator

Leukaemia Care Updated Patient Information - Richter's Syndrome in Chronic Lymphocytic Leukaemia

Leukaemia Care is a UK charity so the support information is UK based. However the information...
Jm954 profile image
Administrator